Linker Information
General Information of This Linker
| Linker ID |
LIN0EQKWD
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
A cleavable hydrophilic linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
IPH45 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Key inclusion: Nectin-4-expressing unresectable/metastatic solid tumors, prior systemic therapy, measurable disease (RECIST 1.1), adequate organ function. Key exclusion: brain metastases, active/latent infections, ILD, recent thromboembolic/cardiovascular events, recent surgery or immunosuppressive therapy, CYP3A4 modifiers, or live vaccines within specified periods.
Click to Show/Hide
|
||||
| Administration Dosage |
Part 1 (dose escalation) and Part 2 (dose optimization)
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06781983 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors
|
||||
| Primary Endpoint |
The study evaluates safety and tolerability, monitoring adverse events (AEs, SAEs, TEAEs) and dose-limiting toxicities (DLTs) over 24 months from first dose through treatment and follow-up.
|
||||
| Other Endpoint |
Pharmacokinetic analysis includes assessing Cmax, AUC, and ADA incidence against IPH4502, alongside preliminary antitumor activity metrics (ORR, DoR, PFS) over 24 months from informed consent through treatment and follow-up.
|
||||